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ABSTRACT
Although partial thickness burns are the most frequently reported burn injuries,
there is no consensus on the optimal treatment. The objective of this study was to
compare the clinical effectiveness and scar quality of Flaminal® Forte to silver sul-
fadiazine (Flamazine®) in the treatment of partial thickness burns. In this two-arm
open label multicenter randomized controlled trial, adult patients with acute partial
thickness burns and an affected total body surface area of less than 30% were ran-
domized between Flaminal® Forte and Flamazine® and followed for 12 months.
Dressing changes in the Flamazine® group were performed daily, and in the
Flaminal® group during the first 3 days post burn and thereafter every other day
until complete wound healing or surgery. Forty-one patients were randomly allo-
cated to Flaminal® Forte and 48 patients to Flamazine®. The primary outcome was
time to wound healing, which did not differ between the groups: median 18 days
with Flaminal® Forte (range 8–49 days) versus 16 days with Flamazine® (range
7–48 days; p = 0.24). Regarding the secondary outcomes during hospital admis-
sion, there were no statistically significant differences between the groups concern-
ing need for surgery, pain scores, pruritus, or pain-related and anticipatory anxiety.
More patients in the Flaminal® group developed wound colonization (78% versus
32%, p < 0.001), but the treatment groups did not differ regarding the incidence of
local infections and use of systemic antibiotics. In terms of scar quality, no statisti-
cally significant differences between both treatment groups were found regarding
subjective scar assessment (Patient and Observer Scar Assessment Scale (POSAS)),
scar melanin and pigmentation (DermaSpectrometer®), and scar elasticity and maxi-
mal extension (Cutometer®) during 12 month postburn. In conclusion, time to
wound healing did not differ, but the use of Flaminal® Forte seemed favorable
because less dressing changes are needed which lowers the burden of wound care.
Although various treatment modalities are available for par-
tial thickness burns none of these are generally accepted as
standard or optimal care.1 Since decades, silver sulfadiazine
(SSD), such as Flamazine®, has been used for treatment of
partial thickness burns.1–5 The widespread use of SSD may
be explained by its broad antimicrobial effect in vitro.4,6,7
However, a Cochrane review of clinical studies showed that
SSD does not prevent wound infection better than nonsilver
containing comparators.8 Several studies have also shown
considerable disadvantages of SSD despite its popularity.
SSD is highly toxic to the wound bed, forms a pseudoeschar
that can lead to bacterial proliferation and impaired wound
assessment, requires daily dressing changes and is consis-
tently associated with poorer wound healing of partial thick-
ness burns compared to nonsilver treatments.1,3,9–11
To overcome the limitations of SSD, various local therapies
have been developed. Several systematic reviews showed that in
more than half of the studies that wound healing time was shorter
with viscous dressings (e.g. Flammacerium®, honey based
wound dressings, Silvazine®), solid dressings (e.g. Acticoat®,
Aquacell®, Mepitel®, Biobrane®, and Trancyte®) and biologicals
dressings (e.g. Xenoderm, Amnion) compared with SSD.1,9,12–14
However, only studies with honey based wound dressings
showed consistently better results for wound infection compared
BSPAS The Burn Specific Pain Anxiety Scale
LDI Laser Doppler Imaging
POSAS Patient and Observer Scar Assessment Scale
SSD Silver sulfadiazine
TBSA Total body surface area
Ue Scar elasticity
Uf Scar maximal extension
VAT Visual Analogue Thermometer
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with SSD.13 In general, solid dressings needed less dressing
changes, while their application was found to be more difficult in
some anatomical locations compared to SSD.12 These results
should be interpreted in light of the paucity of high-quality evi-
dence, high risk of bias, limited number of included patients and
unclear role of sponsorship in the majority of the included clinical
trials. Therefore, no firm conclusion regarding the effectiveness
of the studied local treatments of partial thickness burns can be
drawn based on these systematic reviews.
In recent years, Flaminal® Forte (Flen Pharma, Kontich,
Belgium) used for the treatment of burn wounds, has gained
popularity, in particular because Flaminal® Forte does not
requires daily dressing change. Flaminal® Forte is composed
of hydrated alginate polymers with a biologic enzyme system
that is based on glucose oxidase and lactoperoxidase stabi-
lized by guaiacol. Due to its composition, Flaminal® Forte is
expected to have an antimicrobial and continuous debriding
effect.15–17 in vitro studies have shown that Flaminal® Forte
is not toxic to keratinocytes and fibroblasts,15,18 and that it
reduces wound colonization by a wide range of Gram-
negative and Gram-positive micro-organisms.15,18 However,
one retrospective clinical study found significantly more bac-
terial growth in partial thickness burns when treated with
Flaminal® compared to SSD.19 Furthermore, two retrospective
studies showed faster wound healing when partial thickness
burns were treated with Flaminal® compared to SSD.19,20
To the best of our knowledge, there is a paucity of evi-
dence for Flaminal® Forte in the treatment of partial thickness
burns. Available evidence is based on retrospective studies
with a limited number of studied patients and relevant out-
comes. Despite the limitation of these studies, Flaminal®
Forte might have advantages such as faster wound healing
and less dressing changes compared to Flamazine®, while the
preventing effect on wound colonization and infection
remains unclear.
Therefore, we performed a multicenter randomized con-
trolled clinical trial in which the clinical effects, quality of life
and cost-effectiveness of Flaminal® Forte and Flamazine® in
the treatment of partial thickness burns were compared. This
first part of the paper reports on the clinical effectiveness and
scar quality of Flaminal® Forte and Flamazine® during the
clinical treatment phase of partial thickness burns with a
follow-up of 12 months.
MATERIALS AND METHODS
Study design and randomization
In this investigator-initiated, open label, multicenter, ran-
domized controlled trial (RCT) we compared the clinical
effectiveness of Flaminal® Forte versus Flamazine® in the
treatment of partial thickness burns. An extensive descrip-
tion of the study protocol was published previously.21 The
results are reported following the Consolidated Standards of
Reporting Trials (CONSORT) guidelines.22 The study was
conducted in compliance with the ethical rules for human
experimentation that are stated in the 1975 Declaration of
Helsinki and approved by the Medical Research Ethics
Committee Noord-Holland (NL43671.094.13). The study
was registered in the European Clinical Trials Database
(EudraCT number: 2013-000901-21) and the Netherlands
Trial Registry (trial number 4486).
Patients
Patients were enrolled in this study from February 2014
until September 2015 in two burn centers in the Netherlands
(Red Cross Hospital, Beverwijk and Maasstad Hospital,
Rotterdam). In these burn centers, both Flaminal® and
Flamazine® are already commonly used for treating partial
thickness burns. Patients were eligible for the study if they
had partial thickness burns of minimally 1% affected total
body surface area (TBSA) based on clinical evaluation and
Laser Doppler Imaging (possibly in combination with full
thickness burns); were admitted to the hospital within
48 hours of the burn injury; were mentally competent or
temporary incompetent (because of sedation and/or intuba-
tion) and provided written informed consent. The exclusion
criteria were age < 18 years; TBSA of >30%; burns caused
by chemicals, electricity or radiation; if local therapy had
already started; or if the treating physician expected that the
patient would not comply with the study protocol.
Study procedure and randomization
Either the local investigator or the on-call burn physician/
-surgical resident informed the eligible patients about the
study and randomized the participants after they had provided
informed consent. If a patient was temporarily incompetent, a
legal representative of the patient was informed about the
study and provided informed consent. In these cases,
informed consent was obtained from the patient as soon as
possible. If these patients did not confirm the consent pro-
vided by their legal representative, they were withdrawn from
the study. Their collected study data was deleted and the allo-
cated treatment was continued as usual care.
Patients were randomly assigned to treatment with either
Flamazine® or Flaminal® Forte, using the online randomiza-
tion program TenALEA (Trans European Network for Clini-
cal Trials Services). The randomization was stratified by
center and used variably sized blocks in a 1:1 ratio. The
patients and medical staff who provided the burn wound
care could not be blinded because both treatments can be
recognized by their appearance. Also, the observers could
not be blinded because they were involved in the clinical
care of the participants.
Interventions
The patients received treatment with either Flaminal® Forte
(Glucose oxidase-Lactoperoxidase Guaiacol complex of
50 g in 5.5% alginogel) manufactured by Flen Pharma, Bel-
gum, or Flamazine® (containing silver sulfadiazine 10 mg/g
in hydrophilic crème base) manufactured by Sinclair Phar-
maceuticals, Surrey, United Kingdom.
Treatment with Flaminal® Forte consisted of cleaning and
rinsing the burn wound with Prontosan® (containing 0.1%
Polyaminopropyl Biguanide (Polihexanide), Betaine Surfac-
tant and purified water) manufactured by B. Braun, Switzer-
land. Thereafter, a sufficiently thick layer (4–5 mm) of
Flaminal® Forte was applied on a nonadhesive dressing and
applied on the burn wound. A net bandage was used to keep
the dressing in place. Dressings were changed daily during
the first 3 days post burn and thereafter every other day until
complete wound healing or surgery.
Treatment with Flamazine® also started with cleaning and
rinsing the burn wound with Prontosan®, followed by
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application of Flamazine® on the burn wound and coverage
with a net bandage to keep the dressing in place. This proce-
dure was repeated once every 24 hours until the sixth day
post burn. Thereafter, Furacine Soluble Dressing (Furacine
2 mg/g ointment) was applied on the burn wound on the
even postburn days and Flamazine® on the odd postburn
days until complete wound healing or operation. The alter-
nation of treatment in this study arm was justified because
of the cytotoxicity of the silver particles in Flamazine® in
the wound bed when used continuously.
In case of wound colonization or infection, the treatment
with either Flaminal® Forte or Flamazine® was changed to
the relevant treatment based on the results of the wound
culture. Treatment of colonized wounds required daily
dressing changes, which could influence the number of
daily dressing changes in both treatment groups. Need for
split skin graft was evaluated between 10 and 14 days
postburn. Partial thickness burn wounds that were not
expected to heal within 21 days, were excised and skin
grafted, as this leads to a lower risk of hypertrophic scar
formations.23,24 This treatment strategy is standard approach
of treatment of partial thickness burns at the Dutch Burn
Centres. After discharge, patients in both groups were treated
in an outpatient setting according to the local protocol.
Baseline characteristics and outcome measures
The following baseline parameters were collected for both
study arms: age, gender, wound etiology, bacterial con-
tamination at admission, location and type of the wound,
TBSA and co-morbidities. The burn depth of the study
area was accurately determined on day 2–5 post burn by
clinical assessment and Laser Doppler Imaging (LDI),
using a MoorLDI2-Burn Imager™ (Moor Instruments,
UK) and based on predefined criteria.21 Studies demon-
strated that LDI has an accuracy of 95% in combination
with clinical estimation, for assessing burn wound
depth.25,26
The primary outcome was time to wound healing, defined
as the number of days until complete (defined as >95%) ree-
pithelialization of the study area, as judged by two experi-
enced burn specialists during each dressing change.
Secondary outcomes were: The need for operation, per-
formed between 10 and 14 days postburn if the burn wound
was not expected to heal; percentage TBSA of the study
area that was covered with skin graft; postsurgical complica-
tions; number of dressing changes; length of hospital stay;
wound colonization; wound infection; use of systemic anti-
biotics; pain; anxiety; and pruritus. A wound swab was
taken from the study area at admission and twice weekly.
Infection was defined as a combination of skin redness,
pain, swelling, tenderness, warmth, fever, or pus draining
from the wound in presence or absence of wound coloniza-
tion (established by wound culture). Pain of the study area
was assessed every day in the evening (background pain)
and before and during dressing change (procedural pain)
using a Visual Analogue Thermometer (VAT) on a scale
from 0 (no pain) to 10 (worst imaginable pain). Pruritus was
assessed daily in the evening during hospital admission by
use of a VAT on a scale from 0 (no pruritus) to 10 (worst
imaginable pruritus).27 The Burn Specific Pain Anxiety
Scale (BSPAS) was used to assess pain-related and anticipa-
tory anxiety in burn patients on the day of discharge.28,29
BSPAS consists of a nine-item self-report scale from 0 (not
at all) to 100 (the worst imaginable way).
Scar quality
The scar quality of the study area was assessed at 3, 6, and
12 months postburn in the outpatient clinic using different
measurement instruments. First, the Patient and Observer
Scar Assessment Scale (POSAS) was used on a scale from
1 (resembles normal skin) to 10 (worst imaginable scar).
The POSAS is a reliable and validated scar assessment
scale, which is designed to evaluate scars by both profes-
sionals and patients. The questionnaire consists of two sepa-
rate six-item scales: the Patient Scar Assessment Scale
(patient scale) and the Observer Scar Assessment Scale
(observer scale). The six items scored by the patient are
pain, itching, color, stiffness, thickness, and irregularity. The
six items scored by the observer are vascularization, pig-
mentation, thickness, relief, pliability, and surface area.30,31
Second, the DermaSpectrometer® (Cortex Technology,
Hadsund, Denmark) was used to measure the scar erythema
(color) and melanin (pigmentation). It is a validated instru-
ment to measure scar vascularization (erythema) and pig-
mentation (melanin) by a narrow band simple reflectance
meter. Results were calculated as absolute difference
between scar tissue and the nonaffected skin.32 Finally, scar
elasticity (Ue) and maximal extension (Uf) in mm were
measured with the Cutometer® (Courage & Khazaka GmbH,
Cologne, Germany). Cutometer® is a validated instrument to
measure the vertical deformation of the skin in millimeters
when the skin is pulled by means of a controlled vacuum
into a circular aperture. Results represent the ratio between
scar tissue and nonaffected skin.33
Sample size calculation
Based on a retrospective study of 70 patients with partial
thickness burns,20 we expected wound healing in 11 days
on average with Flamazine® and 6 days on average with
Flaminal® (pooled standard deviation 7.5 days). To identify
such a clinically relevant difference regarding time to com-
plete epithelialization between the treatment arms (with 80%
power and alpha 5%), it was calculated that 41 patients per
arm were needed. Assuming a 10% attrition rate, the sample
size was fixed at 45 patients in each arm.
Statistical analysis
The data analysis was performed according to the intention-
to-treat principle using IBM SPSS Statistics for Windows,
version 22 (IBM Corp., Armonk, NY). The baseline patient
characteristics were described as mean  standard deviation
for normally distributed continuous variables, as median
(range) for skewed continuous variables, and as number
(proportion) for categorical variables. The difference in time
to complete reepithelialization was compared in both treat-
ment groups and analyzed with Kaplan–Meier curves and
log rank test. To correct for potentially confounding vari-
ables, a multivariable Cox regression analysis was per-
formed to confirm the primary analysis.
The secondary clinical and patient-reported outcomes on
specific follow-up moments was compared between the treat-
ment groups using a two-sided t-test or Mann–Whitney test for
continuous data, and a two-sided Chi-square test or Fisher’s
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exact test for categorical data. Repeatedly measured study
parameters (pain, pruritus, and scar quality) were analyzed
using a linear mixed model with treatment as fixed effect and
patient as random effect. To check for effect-modification of
the treatment differences by time, an interaction term (treat-
ment*time) was added in the models. In the analyses a p-value
<0.05 was considered statistically significant.
RESULTS
Inclusion and baseline characteristics
From February 2014 until September 2015, 135 patients
were eligible for the study, of whom 90 were randomized
(Figure 1). Twelve patients were withdrawn from the study
Assessed for eligibility: 634 patients 
Excluded      544 
 Not meeting inclusion criteria  499 
 Missed    40 
 Declined to participate  5 
Allocated to Flamazine®   45 
Post-randomization exclusion    2 
 No consent after detubation    2 
Allocated to Flaminal® Forte    45 
Post-randomization exclusion   10 
 No consent after detubation    3 
 Mis estimation of TBSA   
at admission     2 
 Language problem    2 
 Received other treatment 
than study treatment    1 
 No follow-up possible 
because of residence abroad   2 
Allocation
Analysed       48 
Withdrawn from the study      0
Analysis 
Analysed     41 
Withdrawn from the study     0
Randomized: 90 patients 
Enrollment 
Received allocation intervention  42 
Discontinued participation    1 
Received allocation intervention  48 
Discontinued participation   0
Replacement of 12 patients who were excluded post-randomization
Figure 1. Flowchart of patients.
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within 2 weeks after randomization for the following rea-
sons: Five patients who had been intubated due to inhalation
injury did not confirm the consent provided by their legal
representative after detubation, two patients did not suffi-
ciently speak the Dutch language, two patients lived outside
of the Netherlands and could therefore not take part in the
follow-up, two patients had TBSA of >30% after reassess-
ment of the wound during admission and one patient
received other treatment than the allocated study treatment.
The Medical Research Ethics Committee gave permission to
randomize 12 more patients to replace the withdrawn
patients and meet the required sample size. Eventually,
90 patients were included in the study, of whom 42 were
randomized for treatment with Flaminal® Forte and 48 for
treatment with Flamazine®. The imbalance in patient num-
bers between the study groups was caused by the additional
inclusion of 12 patients replacing the patients who were
excluded after randomization. A major protocol violation
occurred in one patient who was randomized for Flaminal®
Forte but crossed over to treatment with Flamazine® because
of high pain levels with Flaminal® Forte during dressing
changes.
The baseline characteristics of the analyzed patients are
presented in Table 1. The patients in the Flaminal group were
on average 7.6 years older compared with the Flamazine®
group. The treatment groups were comparable regarding gen-
der, percentage TBSA of the study area, trauma mechanism,
anatomical location of the study area, comorbidity and
wound colonization at admission.
According to the protocol, dressing changes were less
often performed during hospital admission in the Flaminal®
group compared to the Flamazine® group (p < 0.0001):
while the dressings of the patients in the Flamazine® group
were changed every day, the dressings of the patients in the
Flaminal group were changed on median 85% of the days
admitted in hospital (range 52–100%).
Primary outcome: wound healing
The median time to wound healing in the Flaminal® group
was 18 days (range 8–49 days) compared with 16 days
(range 7–48 days, Mann–Whitney test p = 0.24) in the
Flamazine® group. Figure 2 shows the Kaplan–Meier curves
of time to wound healing for the Flaminal® group and the
Flamazine® group (log-rank test, p = 0.44). Given that the
patients in the Flaminal group were on average more than
7 years older, a Cox proportional hazards model was per-
formed to adjust for age, showing no difference in time to
wound healing (hazard ratio 0.89 for Flaminal compared to
SSD, 95% confidence interval [CI] 0.58–1.35, p = 0.58). In
the model, age was not associated with time to wound heal-
ing (hazard ratio per one-year increase 0.99, 95% CI
0.98–1.00, p = 0.19). Furthermore, no difference was found
between the treatment groups with respect to time to wound
healing of the nonoperated study area.
Table 1. Baseline characteristics
Characteristic
Flaminal
(n = 41)
Flamazine®
(n = 48)
Age in years, mean (SD) 50.2 (15.4) 42.6 (16.2)
Male gender, n (%) 32 (78) 39 (81)
Smoking, n (%) 12 (29) 16 (34)
%TBSA study area,
median (range)
• Partial thickness burns 3 (0.75–10) 3 (0.5–16)
• Superficial 1 (0–9) 1 (0–4)
• Intermediate 0.5 (0–3.5) 0.8 (0–7)
• Deep 0.25 (0–4) 0.18 (0–15)
On ventilation, n (%) 6 (15) 8 (17)
Duration in days,
median (range)
3 (1–19) 3.5 (1–10)
Trauma mechanism, n (%)
• Scald 4 (10) 7 (15)
• Flame 20 (49) 21 (44)
• Flash 12 (29) 16 (33)
• Hot grease 2 (5) 4 (8)
• Hot steam 3 (7) 0 (0)
Location of study area, n (%)
• Head and neck 1 (2) 1 (2)
• Trunk (anterior) 10 (24) 6 (13)
• Trunk (posterior) 6 (15) 2 (4)
• Upper extremities 16 (39) 24 (50)
• Lower extremities 8 (20) 15 (31)
Comorbidity, n (%)
• Diabetes 2 (5) 3 (6)
• Cardiovascular 8 (20) 3 (6)
• Renal disease 0 (0) 1 (2)
• Obesity 2 (5) 1 (2)
• Psychiatric disorder 6 (15) 2 (4)
• Malignancy 2 (5) 0 (0)
Colonization on
admission, n (%)
4 (10) 8 (17) Figure 2. Kaplan–Meier curves for time to wound healing of
partial thickness burn in the Flaminal® Forte and Flamazine®
group.
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Surgical outcomes
No difference was found between the treatment groups
regarding need for operation, percentage of the study area
covered with skin graft, complications after surgery and
length of hospital stay (Table 2).
Wound colonization and infection
At admission, four patients in the Flaminal® group and eight
in the Flamazine® group already had colonized burn
wounds. Of the initially not colonized wounds, 29 (78%) in
the Flaminal group developed wound colonization during
admission compared to 13 (33%) in the Flamazine® group
(p < 0.0001; Table 3). The number of days until wound col-
onization did not differ between treatment groups, nor did
the local infection rate and the use of systemic antibiotics
between the treatment groups (Table 3). The microbiology
of the colonized burn wounds is described in Table 3. The
studied burn wounds were mainly colonized by Gram+
microorganisms, mostly Staphylococcus aureus.
Pain, anticipatory anxiety, and pruritus
Pain before and during dressing changes decreased signifi-
cantly over time during hospital admission in both treatment
groups (Figure 3A and B). In the model, the mean decrease
in pain score before dressing change was 0.10 points per
day (95% CI 0.08–0.12, p < 0.0001) and the mean decrease
in pain score during dressing change was 0.13 points per
day (95% CI 0.11–0.15, p < 0.0001). No difference in pro-
cedural pain was seen for the Flaminal® group compared to
the Flamazine® group for pain before dressing change (mean
difference 0.10, 95% CI −0.56 to 0.77, p = 0.76), nor for
pain during dressing change (mean difference 0.26, 95% CI
−0.45 to 0.97, p = 0.47). Scores for background pain (mea-
sured in the evening) also decreased over time during hospi-
tal admission by an average of 0.07 points per day (95% CI
0.05–0.09, p < 0.0001), but did not differ between the treat-
ment groups (p = 0.89; Figure 3C).
Pain-related and anticipatory anxiety during admission
was comparable in the treatment groups: the median BSPAS
score in the Flaminal® group was 35 (range 0–78) compared
with 26 (range 0–82) in the Flamazine® group (Mann–
Whitney test p = 0.45).
The scores for pruritus of the study area increased slightly
over time during hospital admission by on average 0.02
points per day (95% CI 0.01–0.04, p = 0.004; Figure 3D).
Table 2. Outcome measures—intention-to-treat analyze
Outcome measure
Flaminal®
Forte
(n = 41)
Flamazine®
(n = 48) p
Time to wound healing
(days)*, median (range)
18 (8–49) 16 (7–48) 0.24†
Time to wound healing of
nonoperated study area,
median (range)
14.5 (8–27) 11 (7–29) 0.07†
Length of hospital stay,
median (range)
16 (1–33) 17 (2–102) 0.79†
Need for operation, n (%) 21 (51) 24 (50) 0.91⊥
%TBSA of study area
covered with skin graft,
median (range)
1.5 (0–5) 0.9 (0–6) 0.20†
Complication after
surgery, n
3/21 4/24 (not tested)
• Hematoma 1/21 0/24
• Graft migration 1/21 0/24
• Graft loss 1/21 3/24
• Wound infection 0/21 1/24
• Allergic reaction 0/21 1/24
• Reoperation 0/21 1/24
*Defined as reepithelialization >95%.
†Mann–Whitney test.
⊥Chi-square test.
Table 3. Wound colonization and infection
Outcome measure
Flaminal®
Forte
(n = 41)
Flamazine®
(n = 48) p
Colonization of
study area, n (%)*
29/37 (78) 13/40 (33) <0.0001†
Time to colonization
of study area in days,
median (range)
5 (2–11) 4 (2–19) 0.36⊥
Species, n (not tested)
Gram+
• Bacillus species 3 1
• Gram-positive
(unspecified)
1 0
• Group B streptococcus 2 0
• Staphylococcus aureus 24 9
Gram−
• Acinetobacter species 1 0
• Aeromonas sobria 0 1
• Enterobacter Faecalis 3 0
• Gram-negative
bacteria (unspecified)
0 1
• Klebsiella Oxytoca 0 1
• Pseudomonas
aeruginosa
2 0
Infection of study
area, n (%)
4/41 (10) 1/48 (2) 0.18¶
Use of systemic
antibiotics, n (%)
0/4 0/1 (not tested)
*Wounds which were colonized at admission were excluded.
†Chi-square test.
⊥Mann–Whitney test.
¶Fisher’s exact test.
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No difference in scores for itching was found between the
treatment groups (p = 0.52).
Scar quality
Results on subjective and objective scar quality are shown
in Table 4. POSAS general impression score for both patient
and observer score showed statistically significant decrease
during the first 12 months postburn (p < 0.0001), while no
statistically significant difference was found between both
treatment groups during the first 12 months postburn
(POSAS patient general impression p = 0.32; POSAS
observer general impression score p = 0.73). A complete
overview of POSAS individual items for patients and
observers are shown in Supplement A.
The absolute difference between scar tissue and the nonaf-
fected skin for erythema and melanin, as assessed by the
DermaSpectrometer®, showed a statistically significant decrease
(p < 0.0001) during the first 12 months postburn. However, no
statistically significant difference was found between both treat-
ment groups in respect to erythema (p = 0.68) or mela-
nin (p = 0.97).
The ratio between scar tissue an nonaffected skin for max-
imal scar extension (Uf) and scar elasticity (Ue), as assessed
by Cutometer®, showed a statistically significant decrease
during the first 12 months postburn (p < 0.00001). No sta-
tistically significant difference was found between both
treatment groups in respect to Uf (p = 0.97) or Uf
(p = 0.90) during the first 12 months postburn.
DISCUSSION
This study is the first randomized controlled trial comparing
the clinical effectiveness of Flaminal® Forte with Flamazine®
in the treatment of partial thickness burns. No statistically
Figure 3. Mean scores for (A) pain before dressing change, (B) pain during dressing change, (C) background pain and
(D) pruritus of the study area in the Flaminal group (solid line) and Flamazine® group (dotted line). Scores are presented up to
20 days postburn; scores thereafter are not shown as these were considered too variable due to the small numbers of
observations.
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significant or clinically relevant differences were found between
the interventions with respect to the wound healing. Further-
more, the need for surgery, pain during dressing changes,
pain-related and anticipatory anxiety or pruritus did not differ
significantly between the treatment groups. In the Flaminal®
group, there were twice as many wound colonizations during
treatment than in the Flamazine® group. Although the inci-
dence of wound infection seemed higher in the Flaminal®
group, the difference was not statistically significant. Note-
worthy, patients treated with Flaminal® Forte required less
dressing changes than the patients treated with Flamazine®.
Interestingly, time to wound healing was not significantly
different between both treatment groups. This finding is in
contrast with previous retrospective studies that described a
better wound healing of partial thickness burns that were
treated with Flaminal® Forte in comparison with SSD.19,20
Selection bias in these retrospective studies may have con-
tributed to this finding. In the current study, the alternated
treatment strategy with Furacine Soluble Dressing from 6th
post burn day in the Flamazine® group may have minimized
the cytotoxicity of the silver particles in the SSD on the
wound bed. Silver is highly toxic to keratinocytes and
Table 4. Subjective and objective scar assessment
Flaminal® Forte Flamazine®
No. (valid) Median Range No. (valid) Median Range p*
Subjective scar assessment
POSAS patient score†
General impression
3 months post burn 35 5 1–10 42 4 1–10 0.70
6 months post burn 34 4 1–10 41 3 1–10 0.30
12 months post burn 35 3 1–10 38 2 1–10 0.09
POSAS observer score⊥
General impression
3 months post burn 35 5 1–10 42 4 1–10 0.70
6 months post burn 34 4 1–10 41 3 1–10 0.30
12 months post burn 35 3 1–10 38 2 1–10 0.09
Objective scar assessment
Scar color (erythema)¶,††
3 months post burn 35 11.0 0.24–27.9 42 9.5 0.66–37.1 0.65
6 months post burn 35 5.8 0–28.3 41 5.3 0.43–27.7 0.37
12 months post burn 35 3.2 0.07–17.4 35 3.3 0.5–10.5 0.24
Scar pigmentation (melanin)**,††
3 months post burn 35 6.7 0.3–28.5 42 8.0 0.1–25.0 0.53
6 months post burn 35 3.3 0.4–15.0 35 4.2 0.07–12.8 0.84
12 months post burn 39 3.7 0–17.4 39 2.6 0.3–18.4 0.59
Scar extension (Uf)⊥⊥,***
3 months post burn 35 0.70 0.35–1.58 40 0.70 1.40–1.60 0.86
6 months post burn 35 0.73 0.20–1.28 41 0.74 0.06–1.31 0.86
12 months post burn 35 0.84 0.29–1.35 40 0.79 0.47–1.60 0.75
Scar elasticity (Ue)¶¶,***
3 months post burn 35 0.62 0.22–1.36 35 0.60 0.20–1.94 0.50
6 months post burn 35 0.62 0.09–1.27 41 0.60 0.35–1.33 0.86
12 months post burn 35 0.78 0.19–1.35 40 0.70 0.36–1.57 0.71
*Mann–Whitney U test.
†Patient and Observer Scar Assessment Scale (POSAS) general impression score provided by the patient.
⊥Patient and Observer Scar Assessment Scale (POSAS) general impression score provided by the observer.
¶Scar color (Erythema) obtained by the DermaSpectrometer®.
**Scar pigmentation (Melanin) obtained by the DermaSpectrometer®.
††Values were calculated as absolute difference between scar tissue and the nonaffected skin.
⊥⊥Scar extension results (Uf) obtained by the Cutometer®.
¶¶Scar elasticity (Ue) obtained by the Cutometer®.
***Values represent the ratio between scar tissue and nonaffected skin.
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fibroblasts in vitro.3,10,11,15 In effect, this treatment strategy
may have limited the poor wound healing that is often seen
in burn wounds treated with SSD for a longer period of
time.3,9,12,34 This use of Flamazine®/Furacine Soluble Dress-
ing may have resulted in no difference in time to wound
healing between both treatments. Overall, rapid wound heal-
ing is vital, because delayed wound healing time is found to
be a risk factor for worse scar quality.23,24,35 Cubison et al.
concluded that the risk of developing a hypertrophic scar was
high when the wound healing took more than 21 days.23
A recent study found that the scar quality worsens with
an increase in time to wound healing, as measured by the
Vancouver Scar Scale (VSS).35
Besides a comparable time to wound healing, the treat-
ment groups also did not differ regarding the need for sur-
gery and size of the study area that required skin grafting.
From a clinical perspective, this means that both treatments
equally reduce the number of operations of the deep partial
thickness burns that are most likely not to heal spontane-
ously. At the Dutch Burn Centers burn wounds are grafted
when no wound healing is expected within 21 days postburn
to minimize the risk of hypertrophic scar formation. This is
likely the reason for the high percentage of grafted burn
wounds in the current study. The favorable results on scar
quality in the current study support this approach. However,
this treatment strategy might also have confounded results
on wound healing.
Dressing changes in both treatment groups were applied
according to the manufacturer recommendations. Therefore,
number of dressing changes was not an outcome in this
study. However, it is essential to have more insight into
dressing changes and its effect on the patient because burn
wound pain is most intense during dressing changes (proce-
dural pain).36,37 Procedural pain is recognized to be a multi-
dimensional experience that often induces significant
anxiety and distress in burn patients.38 The management of
this type of burn pain is challenging for burn specialists,
especially in absence of a consensus on treatment strategy.39
Therefore, less dressing changes could contribute to mini-
mize burn wound pain, anxiety and distress. In the current
study, dressing changes were less often performed during
hospital admission in the Flaminal® group compared to the
Flamazine® group (p < 0.0001): while the dressings of the
patients in the Flamazine® group were changed every day,
the dressings of the patients in the Flaminal group were
changed on median 85% of the days admitted in hospital
(range 52–100%). As a result, patients in the Flaminal®
group had less moments of procedural pain compared to the
patients in the Flamazine® group during hospital admission.
Despite the higher incidence of wound colonization in the
Flaminal® group, no significant differences in the incidence
of wound infection, use of systemic antibiotics or quality of
wound healing were observed compared with the
Flamazine® group. This observation is in line with a previ-
ous retrospective study by Hoeksema et al.19 There are sev-
eral explanations for this finding. First, wound colonization
alone, in the absence of tissue damage, may not delay the
wound healing process.40 Studies indicated that subinfective
levels of bacteria may even be required for the formation of
granulation tissue and collagen formation to accelerate the
wound healing process.41,42 However, a transient stage from
wound colonization to critical colonization or wound infec-
tion is likely to result in delayed wound healing.40 This
theory supports our results as no difference in incidence of
wound infection and time to wound healing was found
between the treatment groups. Second, the continuous
debridement effect of Flaminal® Forte may reduce the bac-
terial load in the presence of wound colonization. How-
ever, this theory was not studied in the present study and
should be examined in future studies. Third, wound coloni-
zation in our study was treated based on the results of the
wound culture. This may have prevented a higher inci-
dence of wound infection and, consequently, have pre-
vented a delayed wound healing in colonized burn wounds
in this study. Fourth, one might speculate that less wound
colonization in the Flamazine® group could be explained
by the alternated treatment strategy in the Flamazine®
group from the 6th postburn day. However, the median
time to first wound colonization in the SSD group was
4 days (range 2–19). On the other hand, the statistical
power of the study was insufficient to ascertain a statisti-
cally significant difference in the incidence of wound
infection between the treatment groups.
In terms of scar quality, no statistical differences were found
between both treatment groups. The POSAS score by both
patient and observer were low and decreased during a follow-
up of 12 months. In line with these findings, the melanin and
the erythema indices measured by DermaSpectrometer® and
scar elasticity and maximal extension measured by Cutometer®
were also improved during follow-up of 12 months, which cor-
responds with improvement of scar quality in both treatment
groups. This finding is important because scar formation nega-
tively impacts quality of life not only in terms of physical limi-
tations and appearance but also in terms of psychological
problems including social anxiety, depression, posttraumatic
stress and poor body image.43–45
The current study has some limitations. First, randomiza-
tion would ideally have been performed after LDI for an
optimal evaluation of the burn wound depth of the study
area. However, in order to get reliable results LDI has to be
performed between 2 and 5 days post burn.25,26 Local treat-
ment could not be started before LDI was performed if ran-
domization was performed after LDI. Consequently, burn
wounds that are untreated before performing LDI are prone
to delayed wound healing. Alternatively, when a local treat-
ment other than Flammazine® or Flaminal® Forte was
started before LDI, a bias was introduced to the study which
may have affected the wound healing time. Moreover, the
current study was designed to evaluate our daily clinical
practice for the treatment of partial thickness burns in two of
the three Dutch Burn Centres. In both centers local treatment
is started directly after admission. Second, results were not
stratified for superficial and deep partial thickness burns,
because the study area was often partial thickness burns with
different depth. This distinction is important because some
authors postulate that standard operative treatment for the
deep partial thickness burns minimizes poor scar quality,
although, there is no consensus in the literature regarding
timing and type of the operation, debridement technique,
use of skin substitutes or application of growth factors and
other humoral agents to enhance wound healing.46–49 Spon-
taneous wound healing of deep partial thickness burns is still
possible because of the surviving keratinocytes and epider-
mal stem cells in the remaining dermis layer.50 Nevertheless,
the reepithelization of deep partial thickness burns is signifi-
cantly prolonged and associated with poor scar quality when
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treated conservatively for more than 21 days.23,24,51 There-
fore, in the current study partial thickness burns were oper-
ated (split skin graft) when the wound healing took more
than 21 days. Moreover, the distribution of superficial, inter-
mediate and deep partial thickness wounds was similar in
the treatment groups, so we believe that the presence of deep
partial thickness burns did not affect the conclusions of our
study. Third, it was not possible to blind the patients and cli-
nicians because of the characteristic appearance of both
treatments. Fourth, the exclusion of psychiatric patients and
children makes the sample not entirely representative. There-
fore, the findings of this study should be extrapolated to
psychiatric and pediatric burn patients with caution. Finally,
the lack of power for our study outcome wound colonization
as mentioned above.
In conclusion, there was no statistically significant or clin-
ically relevant difference in wound healing between
Flaminal® Forte and Flamazine® in the treatment of partial
thickness wounds. Nevertheless, Flaminal® Forte seemed
favorable because of less dressing changes and therefore
lower burden of wound care. More studies are needed to
conform these findings.
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